InsiderDB

Lobbying disclosures · Lobbying report

INCY: third_quarter 2026 lobbying report

Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. Issues related to drug pricing including potential legislation to impose Most Favored Nation pricing in Medicare. CMS Guard demonstration project".

Follow INCY
Became public
Oct 20, 2026, 3:28 PM EDT
Event / period date
Not stated
Collected
Nov 11, 2026, 6:18 PM EST

Why this is connected

Legal-name match: INCYTE CORPORATION is INCYTE CORP (https://www.sec.gov/Archives/edgar/data/879169/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).

Reported lobbying amounts

Income: $60,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/b7b51a1a-1234-4fb8-97b0-d30b2c93df22/","filing_uuid":"b7b51a1a-1234-4fb8-97b0-d30b2c93df22","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/b7b51a1a-1234-4fb8-97b0-d30b2c93df22/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darren Willcox","dt_posted":"2026-10-20T15:28:18-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1455 Pennsylvania Avenue, NW","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":400605842,"url":"https://lda.gov/api/v1/registrants/400605842/","house_registrant_id":null,"name":"W STRATEGIES, LLC","description":"Government Affairs Consulting Firm.","address_1":"1455 Pennsylvania Avenue, NW","address_2":"Suite 400","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DARREN WILLCOX","contact_telephone":"+1 202-494-6268","dt_updated":"2026-07-30T12:17:37.753365-04:00"},"client":{"id":193519,"url":"https://lda.gov/api/v1/clients/193519/","client_id":342,"name":"INCYTE CORPORATION","general_description":"​Biopharmaceutical Company.","client_government_entity":false,"client_self_select":null,"state":"DE","state_display":"Delaware","country":"US","country_display":"United States of America","ppb_state":"DE","ppb_state_display":"Delaware","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-11-11"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to Medicaid Drug Rebate program rule. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - ORPHAN Cures Act. Issues related to drug pricing including potential legislation to impose Most Favored Nation pricing in Medicare. CMS Guard demonstration project\".","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":51473,"prefix":null,"prefix_display":null,"first_name":"DARREN","nickname":null,"middle_name":null,"last_name":"WILLCOX","suffix":null,"suffix_display":null},"covered_position":"Asst. for Policy, Speaker Dennis Hastert; Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss; House Rules Comm. Assoc., Subcommittee Staff Director","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in INCY

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.